Home > Healthcare > Medical Devices > Diagnostic Devices > Breast Cancer Diagnostics Market

Breast Cancer Diagnostics Market Share

Report ID: GMI10383
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Breast Cancer Diagnostics Market Share

The market is highly competitive, with major global companies and smaller to medium-sized firms vying for market leadership. Continuous innovation is crucial, as companies frequently introduce new diagnostic products that utilize advanced technologies like AI-driven image analysis, liquid biopsy, and genomic profiling. Industry leaders maintain their competitive edge through significant investments in research and development, driving groundbreaking advancements in early detection and personalized treatment strategies. Strategic partnerships, acquisitions, and mergers are essential for consolidating market positions and expanding global footprints, allowing companies to address evolving healthcare needs and strengthen their competitive advantage in the dynamic breast cancer diagnostics landscape.

Breast Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the breast cancer diagnostics industry include:

Argon Medical Devices
Becton, Dickinson and Company
Bio-Rad Laboratories, Inc.
Canon Inc.
Danaher Corporation
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd
FUJIFILM Holdings Corporation
Hologic, Inc.
Illumina, Inc.
Koninklijke Philips N.V.
Myriad Genetics, Inc.
QIAGEN N.V.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The breast cancer diagnostics industry size was USD 28.2 billion in 2023 and will grow at 10.2% CAGR from 2024 to 2032 due to rising need for early detection, accurate diagnosis, and effective treatment planning.

The imaging test type segment in the breast cancer diagnostics industry recorded USD 13.2 billion in 2023 owing to its crucial role in detecting and diagnosing breast cancer at various stages.

The breast cancer diagnostics industry from the diagnostic and predictive application segment accounted for USD 13.5 billion in 2023 attributed to its pivotal role in early detection and personalized treatment planning.

U.S. breast cancer diagnostics industry size is projected to reach USD 27.2 billion by 2032 led by significant investments in healthcare innovation and technology